Ashton; Mark Richard
Patent Applications and Registrations
Patent applications and USPTO patent grants for Ashton; Mark Richard.The latest application filed is for "spiroindolinepiperidine derivatives".
- Ashton; Mark Richard - Abington GB
- Ashton; Mark Richard - Abingdon GB
- Ashton; Mark Richard - Oxford GB
- Ashton; Mark Richard - Didcot GB
| Patent | Date |
|---|---|
| Spiroindolinepiperidine derivatives Grant 9,686,990 - Hughes , et al. June 27, 2 | 2017-06-27 |
| Spiroindolinepiperidine Derivatives App 20160007608 - Hughes; David John ; et al. | 2016-01-14 |
| Spiroindolinepiperidine derivatives Grant 9,174,987 - Hughes , et al. November 3, 2 | 2015-11-03 |
| Treatment of CRTH2-mediated diseases and conditions Grant 8,314,257 - Middlemiss , et al. November 20, 2 | 2012-11-20 |
| Treatment of CRTH2-mediated diseases and conditions Grant 8,198,314 - Middlemiss , et al. June 12, 2 | 2012-06-12 |
| Treatment of CRTH2-mediated diseases and conditions Grant 8,163,931 - Middlemiss , et al. April 24, 2 | 2012-04-24 |
| Treatment of CRTH2-mediated diseases and conditions Grant 8,163,936 - Middlemiss , et al. April 24, 2 | 2012-04-24 |
| Spiroindolinepiperidine Derivatives App 20120010220 - Hughes; David John ; et al. | 2012-01-12 |
| EP.sub.2 receptor agonists Grant 8,080,567 - Oxford , et al. December 20, 2 | 2011-12-20 |
| EP2 Receptor Agonists App 20100261760 - Oxford; Alexander William ; et al. | 2010-10-14 |
| EP.sub.2 receptor agonists Grant 7,803,841 - Oxford , et al. September 28, 2 | 2010-09-28 |
| Ep2 Receptor Agonists App 20100130556 - Oxford; Alexander William ; et al. | 2010-05-27 |
| EP2 receptor agonists Grant 7,662,839 - Oxford , et al. February 16, 2 | 2010-02-16 |
| Ep2 Receptor Agonists App 20090298899 - Oxford; Alexander William ; et al. | 2009-12-03 |
| Compounds for the treatment of CRTH2-mediated diseases and conditions Grant 7,582,672 - Middlemiss , et al. September 1, 2 | 2009-09-01 |
| Treatment of CRTH2-mediated diseases and conditions App 20090023788 - Middlemiss; David ; et al. | 2009-01-22 |
| Treatment of CRTH2-Mediated diseases and conditions App 20090018338 - Middlemiss; David ; et al. | 2009-01-15 |
| Treatment of CRTH2-mediated diseases and conditions App 20090018138 - Middlemiss; David ; et al. | 2009-01-15 |
| Treatment of CRTH2-mediated diseases and conditions App 20090018139 - Middlemiss; David ; et al. | 2009-01-15 |
| Pyrazine Derivatives As Effective Compounds Against Infectious Diseases App 20080194574 - Eikhoff; Jan Eike ; et al. | 2008-08-14 |
| Ep2 Receptor Agonists App 20080119526 - Oxford; Alexander William ; et al. | 2008-05-22 |
| EP2 receptor agonists Grant 7,326,732 - Oxford , et al. February 5, 2 | 2008-02-05 |
| Compounds Having Crth2 Antagonist Activity App 20070232681 - Middlemiss; David ; et al. | 2007-10-04 |
| Spiroindolinepiperidine derivatives App 20060106045 - Hughes; David John ; et al. | 2006-05-18 |
| EP2 receptor agonists App 20050256170 - Oxford, Alexander William ; et al. | 2005-11-17 |
| Treatment of CRTH2-mediated diseases and conditions App 20050119268 - Middlemiss, David ; et al. | 2005-06-02 |
| Phosphine ligands Grant 6,162,951 - Polywka , et al. December 19, 2 | 2000-12-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 